Mallinckrodt recognized as industry innovator at national organization for rare disorders (nord) 2023 rare impact awards
– terlivaz ® (terlipressin) is the only fda approved treatment for adults with hrs with rapid reduction in kidney function1 – dublin , may 5, 2023 /prnewswire/ -- mallinckrodt plc (nyse american: mnk), a global specialty pharmaceutical company, is pleased to announce it has received an award from the national organization for rare disorders (nord), recognizing it as an "industry innovator" for the creation of a treatment "to improve the lives of rare disease patients." mallinckrodt is being recognized for the u.s. food and drug administration (fda) approval of terlivaz ® (terlipressin) for injection for the treatment of adults with hrs with rapid reduction in kidney function.1 terlivaz, the first and only fda-approved product indicated for the treatment of adults with hepatorenal syndrome (hrs) involving rapid reduction in kidney function,1 an acute and life-threatening condition requiring hospitalization,2 was approved for use on september 14, 2022.
MNK Ratings Summary
MNK Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission